Eligibility of metastatic pancreatic adenocarcinoma (MPA) patients for first-line palliative intent nab-paclitaxel plus gemcitabine (NG) versus FOLFIRINOX (FIO).
Renata D'Alpino Peixoto
No relevant relationships to disclose
Daniel John Renouf
No relevant relationships to disclose
Howard John Lim
No relevant relationships to disclose
Winson Y. Cheung
No relevant relationships to disclose